Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Metastatic Triple-Negative Breast Cancer
Interventions: DRUG: Trilaciclib|DRUG: Pembrolizumab|DRUG: Gemcitabine|DRUG: Carboplatin
Sponsor: Wake Forest University Health Sciences
Collaborators: Merck Sharp & Dohme LLC|G1 Therapeutics, Inc.